Production (Stage)
Amylyx Pharmaceuticals, Inc.
AMLX
$5.31
-$0.05-0.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.61% | -99.59% | -101.04% | 24.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.61% | -99.59% | -101.04% | 24.10% |
| Cost of Revenue | -85.54% | -124.53% | 65.22% | -11.15% | 419.13% |
| Gross Profit | 65.64% | -76.66% | -185.76% | -149.99% | -253.44% |
| SG&A Expenses | -72.85% | -67.27% | -63.41% | -50.11% | 31.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -82.06% | -62.46% | -9.40% | -3.53% | 186.84% |
| Operating Income | 69.05% | -2,202.07% | -504.17% | -477.63% | -5,848.86% |
| Income Before Tax | 69.71% | -689.58% | -424.41% | -402.83% | -8,549.82% |
| Income Tax Expenses | -- | -136.39% | -- | -- | 242.35% |
| Earnings from Continuing Operations | 69.77% | -893.62% | -447.98% | -429.35% | -7,652.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 69.77% | -893.62% | -447.98% | -429.35% | -7,652.00% |
| EBIT | 69.05% | -2,202.07% | -504.17% | -477.63% | -5,848.86% |
| EBITDA | 69.09% | -1,911.81% | -496.59% | -471.44% | -6,488.16% |
| EPS Basic | 76.07% | -879.77% | -444.53% | -425.53% | -7,518.22% |
| Normalized Basic EPS | 76.02% | -1,263.55% | -421.13% | -399.28% | -8,435.88% |
| EPS Diluted | 76.07% | -888.76% | -456.67% | -445.16% | -8,853.50% |
| Normalized Diluted EPS | 76.02% | -1,298.40% | -432.32% | -412.30% | -8,906.45% |
| Average Basic Shares Outstanding | 26.30% | 1.75% | 1.00% | 1.18% | 1.70% |
| Average Diluted Shares Outstanding | 26.30% | -0.87% | -2.38% | -3.00% | -4.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |